Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the recipient of some unusual options trading activity on Friday. Stock traders purchased 100,752 call options on the stock. This is an increase of approximately 58% compared to the average daily volume of 63,882 call options.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. BMO Capital Markets reissued a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Finally, HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Four research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $64.94.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk A/S Stock Down 1.7%

NYSE NVO traded down $0.81 on Friday, reaching $45.91. The company had a trading volume of 10,833,924 shares, compared to its average volume of 12,845,990. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The firm has a 50-day moving average of $47.36 and a 200-day moving average of $44.51. The firm has a market capitalization of $204.99 billion, a PE ratio of 11.23, a P/E/G ratio of 4.23 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The company had revenue of $11.98 billion for the quarter. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be paid a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s payout ratio is 42.79%.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 6.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Novo Nordisk A/S by 5.1% in the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley boosted its holdings in Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after purchasing an additional 428,660 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Novo Nordisk A/S during the 1st quarter valued at approximately $287,660,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.